Netherlands-based artificial intelligence (AI) firm Aidence has received CE Mark regulatory approval for version 2 of its Veye Chest pulmonary nodule detection software.
In addition to automating the detection of pulmonary nodules, Veye Chest version 2 can determine nodule diameter, volume, growth rate, and composition. In effect, the software can automate the entire process of nodule management, according to the firm.
The accuracy of these new features has been validated in a clinical study recently conducted at National Health Service (NHS) Lothian and the University of Edinburgh in the U.K. Several hospitals in the Netherlands are currently testing the software and plan to upgrade their Veye Chest software to version 2 in September, Aidence said.
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnieeurope.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
